Trastuzumab resistance: all roads lead to SRC

被引：24

作者：

Muthuswamy, Senthil K. ^{[1
,2
]}

机构：

[1] Univ Toronto, Ontario Canc Inst, Campbell Family Breast Canc Res Inst, Toronto, ON, Canada

[2] Cold Spring Harbor, Cold Spring Harbor Lab, New York, NY USA

来源：

NATURE MEDICINE | 2011年 / 17卷 / 04期

关键词：

METASTATIC BREAST-CANCER; MONOCLONAL-ANTIBODY; PTEN; PLUS;

D O I：

10.1038/nm0411-416

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

[No abstract available]

引用

页码：416 / 418

页数：4

共 15 条

[1] Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth [J].

Agus, DB ;

Akita, RW ;

Fox, WD ;

Lewis, GD ;

Higgins, B ;

Pisacane, PI ;

Lofgren, JA ;

Tindell, C ;

Evans, DP ;

Maiese, K ;

Scher, HI ;

Sliwkowski, MX .

CANCER CELL, 2002, 2 (02) :127-137

[2] Phase I Study of Everolimus Plus Weekly Paclitaxel and Trastuzumab in Patients With Metastatic Breast Cancer Pretreated With Trastuzumab [J].

Andre, Fabrice ;

Campone, Mario ;

O'Regan, Ruth ;

Manlius, Corinne ;

Massacesi, Cristian ;

Sahmoud, Tarek ;

Mukhopadhyay, Pabak ;

Soria, Jean-Charles ;

Naughton, Michael ;

Hurvitz, Sara A. .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (34) :5110-5115

[3] Phase II study of weekly intravenous recombinant humanized Anti-p185(HER2) monoclonal antibody in patients with HER2/neu-overexpressing metastatic breast [J].

Baselga, J ;

Tripathy, D ;

Mendelsohn, J ;

Baughman, S ;

Benz, CC ;

Dantis, L ;

Sklarin, NT ;

Seidman, AD ;

Hudis, CA ;

Moore, J ;

Rosen, PP ;

Twaddell, T ;

Henderson, IC ;

Norton, L .

JOURNAL OF CLINICAL ONCOLOGY, 1996, 14 (03) :737-744

[4] Randomized Study of Lapatinib Alone or in Combination With Trastuzumab in Women With ErbB2-Positive, Trastuzumab-Refractory Metastatic Breast Cancer [J].

Blackwell, Kimberly L. ;

Burstein, Harold J. ;

Storniolo, Anna Maria ;

Rugo, Hope ;

Sledge, George ;

Koehler, Maria ;

Ellis, Catherine ;

Casey, Michelle ;

Vukelja, Svetislava ;

Bischoff, Joachim ;

Baselga, Jose ;

O'Shaughnessy, Joyce .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (07) :1124-1130

[5] Neratinib, an Irreversible ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced ErbB2-Positive Breast Cancer [J].

Burstein, Harold J. ;

Sun, Yan ;

Dirix, Luc Y. ;

Jiang, Zefei ;

Paridaens, Robert ;

Tan, Antoinette R. ;

Awada, Ahmad ;

Ranade, Anantbhushan ;

Jiao, Shunchang ;

Schwartz, Gary ;

Abbas, Richat ;

Powell, Christine ;

Turnbull, Kathleen ;

Vermette, Jennifer ;

Zacharchuk, Charles ;

Badwe, Rajendra .

JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (08) :1301-1307

[6]

GARRETT JT, 2011, CANCER BIOL THER, V11, P15045

[7] Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers [J].

Ghosh, Ritwik ;

Narasanna, Archana ;

Wang, Shizhen Emily ;

Liu, Shuying ;

Chakrabarty, Anindita ;

Balko, Justin M. ;

Gonzalez-Angulo, Ana Maria ;

Mills, Gordon B. ;

Penuel, Elicia ;

Winslow, John ;

Sperinde, Jeff ;

Dua, Rajiv ;

Pidaparthi, Sailaja ;

Mukherjee, Ali ;

Leitzel, Kim ;

Kostler, Wolfgang J. ;

Lipton, Allan ;

Bates, Michael ;

Arteaga, Carlos L. .

CANCER RESEARCH, 2011, 71 (05) :1871-1882

[8] Drug therapy: Trastuzumab - Mechanism of action and use in clinical practice [J].

Hudis, Clifford A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2007, 357 (01) :39-51

[9] Src family protein-tyrosine kinases alter the function of PTEN to regulate phosphatidylinositol 3-kinase/AKT cascades [J].

Lu, YL ;

Yu, QH ;

Liu, JH ;

Zhang, JY ;

Wang, HW ;

Koul, D ;

McMurray, JS ;

Fang, XJ ;

Yung, WKA ;

Siminovitch, KA ;

Mills, GB .

JOURNAL OF BIOLOGICAL CHEMISTRY, 2003, 278 (41) :40057-40066

[10] Advances in Targeting Src in the Treatment of Breast Cancer and Other Solid Malignancies [J].

Mayer, Erica L. ;

Krop, Ian E. .

CLINICAL CANCER RESEARCH, 2010, 16 (14) :3526-3532

← 1 2 →